U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
Dec. 28, 2020: The power of clinic-pharmacy collaborations; overcoming COVID-19-induced barriers to HIV care; urine testing as a PrEP adherence tool; using incarceration history in PrEP Rx assessments.
Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.
PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.
An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.
A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
‘PrEP for Women Too’ Campaign Aims to Bring This Empowering HIV Prevention Tool to More Black and Latinx Women
Despite PrEP being safe to take for people of all genders, there’s still a lag in uptake among cisgender women.
Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.
Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.